United Therapeutics Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020	2019	2018 - 1997
Net Income	984.8	727.3	475.8	514.8	-104.5	Upgrade
Depreciation & Amortization	53.2	51.3	49.9	49.9	45.9	Upgrade
Share-Based Compensation	39.1	106.8	138.5	163.8	45.4	Upgrade
Other Operating Activities	-99.1	-82.9	-66	27.2	-193.4	Upgrade
Operating Cash Flow	978	802.5	598.2	755.7	-206.6	Upgrade
Operating Cash Flow Growth	21.87%	34.15%	-20.84%	-	-	Upgrade
Capital Expenditures	-230.4	-138.8	-120.8	-56.9	-83.7	Upgrade
Acquisitions	-89.2	8.6	0	0	-12.5	Upgrade
Change in Investments	-400	-681.3	-366.1	-681.6	-239.2	Upgrade
Investing Cash Flow	-719.6	-811.5	-486.9	-738.5	-335.4	Upgrade
Share Issuance / Repurchase	98	88.4	50	33.8	14	Upgrade
Debt Issued / Paid	-102.7	-7.5	0	-51.7	599.3	Upgrade
Other Financing Activities	-7.2	-5.5	-5.2	1	-2.1	Upgrade
Financing Cash Flow	-11.9	75.4	44.8	-16.9	611.2	Upgrade
Net Cash Flow	246.5	66.4	156.1	0.3	69.2	Upgrade
Free Cash Flow	747.6	663.7	477.4	698.8	-290.3	Upgrade
Free Cash Flow Growth	12.64%	39.02%	-31.68%	-	-	Upgrade
Free Cash Flow Margin	32.12%	34.28%	28.32%	47.11%	-20.04%	Upgrade
Free Cash Flow Per Share	15.97	14.59	10.63	15.81	-6.63	Upgrade

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).